After six years of growth, Imanova has been acquired by Invicro to establish a unique imaging and data management company, providing comprehensive services in support of drug development and disease research.
‘Strong support from the MRC and our academic partners has been critical to the successful development and expansion of imaging technology’ said Kevin Cox, Imanova CEO. ‘This acquisition is a recognition of the excellence of UK science and will provide additional resource and expertise to drive innovation in imaging sciences for medical research and help reduce the risk, cost and time of drug development’ Cronin continued.
Founded in 2011 through a unique joint venture between the MRC, Imperial College London, Kings College London and University College London, Imanova has developed expertise in the development of novel imaging biomarkers and analysis techniques and their application in clinical academic research and translational drug development.
Invicro’s acquisition of Imanova will secure over 90 high-tech jobs at the London imaging centre, and will provide substantial inward investment for UK science. Invicro will expand biomarker R&D and broaden the range of imaging services available from the London site by employing expertise in bio-analytics and data management. Through this, Invicro will build on Imanova’s existing collaborations with UK academia.
Dr Jack Hoppin, Invicro CEO says, ‘Invicro is excited to invest in the UK, and Imanova is an ideal partner as the merger of our complementary capabilities will create a unique end-to-end imaging services and data management company that can support our sponsors at all stages of the drug development life-cycle.’
Previous acquisitions by Invicro include Molecular NeuroImaging LLC (MNI) in 2016, which added radioligand development and manufacturing, design and implementation of Phase I to Phase IV clinical trials, and customised clinical imaging site coordination and management in multi-site imaging studies.
